Business
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy
MOUNTAIN VIEW, Calif., December 17, 2025--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that it has filed a Premarket Approval Supplement (PMA-S) application to the U.S. Food and Drug Administration (FDA) seeking to expand the labeled indication for its RNS® System to include patients with antiseizure-medication (ASM) resistant idiopathic generalized epilepsy (IGE) with generalized tonic-clonic seizures.
About this update from Neuropace, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/5f169a776d81d09eb2308e31a04d1e90"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9UeaVkMytwCzKKvLzIAc9w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5f169a776d81d09eb2308e31a04d1e90","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/5fInQi4KQvfnsifyqq6dCw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/5f169a776d81d09eb2308e31a04d1e90","width":1024,"height":512}},"lazy":false},{"type":"text","content":"-- Submission supported by positive preliminary 18-month NAUTILUS data in patients with drug-resistant idiopathic generalized epilepsy (IGE) and generalized tonic-clonic (GTC) seizures --","length":187,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., December 17, 2025--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that it has filed a Premarket Approval Supplement (PMA-S) application to the U.S. Food and Drug Administration (FDA) seeking to expand the labeled indication for its RNS® System to include patients with antiseizure-medication (ASM) resistant idiopathic generalized epilepsy (IGE) with generalized tonic-clonic seizures.","length":517,"tagName":"p"},{"type":"text","content":"The PMA-S is supported by positive preliminary results from the NAUTILUS trial, which demonstrated robust 77% median GTC seizure reduction and a favorable safety profile in this highly refractory patient population at 18 months of therapy. The RNS System has been granted Breakthrough Device Designation for this IGE indication, reflecting the significant unmet clinical need and the potential for the therapy to provide more effective treatment than existing options. Under current FDA guidelines, PMA supplements are typically reviewed within approximately 180 days, although actual review times may vary.","length":607,"tagName":"p"},{"type":"text","content":""Filing the PMA supplement for idiopathic generalized epilepsy is an important milestone in our strategy to make responsive neuro...